Apellis Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 41.03 USD (At close: May 13, 2026) · Market cap 5.25B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glome...